Related Experiment Video

Updated: Mar 13, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K

Hepcidin: an important iron metabolism regulator in chronic kidney disease

Sandra Azevedo Antunes1, Maria Eugênia Fernandes Canziani2

  • 1Hospital Universitário da Universidade Federal de Alagoas.

Jornal Brasileiro De Nefrologia
|October 14, 2016
PubMed

Insights

Anemia in chronic kidney disease (CKD) is linked to high hepcidin levels, impacting iron metabolism. Further research is needed to understand hepcidin

Area of Science:

  • Nephrology
  • Hematology
  • Biochemistry

Background:

  • Anemia is a significant complication in chronic kidney disease (CKD), contributing to increased morbidity and mortality.
  • Hepcidin, a peptide hormone, plays a crucial role in regulating iron homeostasis.
  • Understanding hepcidin's function is key to addressing iron metabolism disorders in CKD anemia.

Purpose of the Study:

  • To review the role of hepcidin in the pathophysiology of anemia in patients with chronic kidney disease.
  • To discuss the factors contributing to elevated hepcidin levels in CKD.
  • To explore the association of high hepcidin with comorbidities and the potential impact of its modulation.

Main Methods:

  • Literature review focusing on hepcidin, iron metabolism, and anemia in the context of chronic kidney disease.
  • Analysis of studies investigating hepcidin production, regulation, and its interaction with ferroportin.
  • Examination of the link between elevated hepcidin and associated conditions like inflammation and oxidative stress.

Main Results:

  • Hepcidin levels are frequently elevated in CKD patients, particularly in advanced stages, due to reduced renal excretion and increased synthesis.
  • Elevated hepcidin impairs iron absorption and release, exacerbating anemia in CKD.
  • High hepcidin concentrations are associated with inflammation, infection, atherosclerosis, insulin resistance, and oxidative stress in CKD.

Conclusions:

  • Hepcidin is a central regulator of iron metabolism, and its dysregulation significantly contributes to anemia in chronic kidney disease.
  • Strategies to modulate hepcidin are being explored, but require further investigation to determine their efficacy and impact on managing CKD anemia.
  • Continued research into hepcidin's role is essential for developing targeted therapies for anemia in CKD patients.

More Related Videos

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

1.0K
Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

5.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
309
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
578
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
536
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
276